Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy.

European journal of haematology - 1 Jul 2026

Treiber Hannes, Ganster Christina, Shirneshan Katayoon, Rittscher Katharina, Brzuszkiewicz Elzbieta, Hasenkamp Justin, Jung Wolfram, Wulf Gerald, Haase Detlef

Abstract excerpt

Myelodysplastic neoplasia (MDS) comprises heterogeneous clonal hematologic disorders characterized by peripheral cytopenia, bone marrow dysplasia, and a risk of leukemic transformation. A hypoplastic variant (MDS-h) shares features with aplastic anemia and responds to immunosuppressive therapy (IST). We report three low-risk MDS-h cases treated with IST and monitored over 9-17 years using serial cytogenetic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Treatment Outcome

Source

Identifiers

PMID: 41910048
DOI: 10.1111/ejh.70179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy.PMID 41910048Read ↗

Evolutionary trajectories of myelodysplastic syndromes/neoplasms.Semantic proximity Read ↗

Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased BlastsSemantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

IL-1β–mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesSemantic proximity Read ↗

Clonal evolution in myelodysplastic syndromes.Semantic proximity Read ↗

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.Semantic proximity Read ↗

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.Semantic proximity Read ↗

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progressionSemantic proximity Read ↗

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapySemantic proximity Read ↗

Diagnosing recipient- vs. donor-derived posttransplant myelodysplastic neoplasm via targeted single-cell mutational profiling.Semantic proximity Read ↗

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.Semantic proximity Read ↗

Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell RemodelingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.